Stock analysts at StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) in a research report issued on Saturday. The firm set a “sell” rating on the stock.
Navidea Biopharmaceuticals Stock Performance
Shares of NAVB opened at $0.00 on Friday. Navidea Biopharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $0.13.
About Navidea Biopharmaceuticals
See Also
- Five stocks we like better than Navidea Biopharmaceuticals
- What Does a Stock Split Mean?
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- How to Most Effectively Use the MarketBeat Earnings Screener
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- P/E Ratio Calculation: How to Assess Stocks
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.